Environmental Protection and Sustainability - The company invested 4.39 million yuan in environmental protection during the reporting period[3]. - The company reduced carbon dioxide equivalent emissions by 101.67 tons through carbon reduction measures[25]. - The company was recognized as a "National Green Factory" and included in the "2023 Carbon Neutral Model Enterprises" list[24]. - The company achieved multiple national energy-saving and environmental certifications for its products, including the US Energy Star certification[24]. - The company is focused on integrating green and innovative development concepts in its product design and manufacturing processes[24]. - The company has implemented internal procedures for pollutant control and hazardous waste management, ensuring compliance with national standards[21]. - The company has developed new products that assist in carbon reduction during the production process[25]. - The company has upgraded its manufacturing processes using advanced production technologies to reduce energy consumption[24]. - The company has established a comprehensive environmental management system from the board level to various functional departments[24]. - The company is committed to sustainable development through energy-efficient technologies and solutions in the medical and pharmaceutical sectors[6]. - The company is focusing on the development of new energy-efficient and low-carbon refrigeration technologies in response to increasing user demands for energy-saving and environmentally friendly products[121]. Financial Performance - The company's operating revenue increased by 0.2% year-on-year, with core business growth sustained and non-storage new industries maintaining rapid growth[43]. - Net profit attributable to shareholders decreased by 7.36% year-on-year, while net profit excluding non-recurring gains and losses decreased by 15.85%[43]. - Basic and diluted earnings per share both decreased by 7.37% year-on-year, primarily due to the cessation of public health prevention business and increased R&D investment[43]. - The company's operating revenue for the first half of the year was CNY 1,270,455,870.90, a slight increase of 0.20% compared to CNY 1,267,878,776.86 in the same period last year[55]. - Net profit attributable to shareholders decreased by 7.36% to CNY 278,462,841.61 from CNY 300,570,997.11 year-on-year[55]. - The net cash flow from operating activities dropped significantly by 38.38% to CNY 113,580,161.42 compared to CNY 184,335,005.22 in the previous year[55]. - The company's total assets at the end of the reporting period were CNY 5,489,422,045.01, showing a marginal increase of 0.01% from CNY 5,488,995,841.72 at the end of the previous year[55]. - Basic earnings per share decreased by 7.37% to CNY 0.88 from CNY 0.95 in the same period last year[55]. - Research and development expenses accounted for 12.40% of operating revenue, an increase of 1.84 percentage points compared to 10.56% in the previous year[55]. Research and Development - The company has developed eight major technology platforms and is actively integrating emerging technologies such as IoT, AI, and cloud computing into its solutions[59]. - The company has established eight major technology platforms, including refrigeration, automation, and separation, and holds 1,111 patents and 250 software copyrights[143]. - The company has established six major R&D and production centers to enhance its multidisciplinary integration and innovation capabilities[109]. - The company has developed a series of innovative low-temperature storage technologies, including a solar-powered vaccine storage system that can maintain vaccine safety for over 135 hours without power[5]. - The company has developed high-performance liquid nitrogen storage technology to reduce nitrogen consumption and achieve long-term low-temperature storage[7]. - The company has developed 4 new microbiological culture media products and is expanding its product line in laboratory reagents and consumables[138]. - The company has achieved industry-leading levels in plasma separation equipment and is developing automated blood component preparation products[139]. - The company has developed an IoT-based smart blood management system that significantly reduces blood transfusion times and improves safety for patients[128]. - The company has filed 306 new patent applications and received 243 patents, indicating a rapid increase in its intellectual property portfolio[133]. - The company’s R&D team is composed of top talents across multiple disciplines, driving innovation and user-centered product development[149]. - The company achieved a total R&D investment of ¥157,574,507.09, representing a 17.71% increase compared to the same period last year, with R&D expenses accounting for 10.56% of total revenue[155]. Market Expansion and Strategy - The company has established long-term partnerships with organizations like WHO and UNICEF, expanding its international market presence to over 40 countries and regions[59]. - The company is focusing on expanding its market presence in the life sciences and medical innovation sectors, leveraging its technological advancements[163]. - The company’s sales model primarily relies on distribution agreements, with a dedicated team for overseas market expansion[62]. - The company has expanded its overseas distributor network to over 800, serving users in more than 140 countries[189]. - The establishment of local warehousing centers in the Netherlands and the U.S. improved local delivery capabilities[191]. - The company achieved significant project deliveries in Ethiopia, Tanzania, and Cameroon, enhancing its international presence[189]. - The company is actively pursuing market expansion and innovation in response to the growing demand for automated and intelligent solutions in the life sciences sector[110]. Product Development and Innovation - New product offerings include comprehensive digital solutions for smart blood management and vaccination, enhancing the company's service portfolio in the healthcare sector[60]. - The company launched new products such as constant temperature incubators and high-capacity centrifuges to meet diverse user needs in cell culture, sterilization, and centrifugation preparation[131]. - The company has launched new products for blood stations, including platelet oscillators and plasma freezers, addressing the recovering user demand[172]. - The automated cell preparation solution developed by the company improved efficiency by 50%, providing a one-stop service for cell preparation processes[152]. - The company is developing a series of ultra-low temperature and low-temperature storage products with a total investment of ¥175,000,000, with significant progress in product development[158]. - The company has introduced an automated sample management platform, leading the industry in automated storage solutions[158]. - The company is focusing on digital transformation, moving from product sales to value-added services, enhancing user engagement and creating lifetime value[145]. - The company’s digital blood management solutions have upgraded from centralized to distributed blood supply models, ensuring "zero waiting" for hospital blood usage[183]. Industry Trends and Insights - The global life science tools market is expected to reach $161.57 billion in 2023, with a CAGR of 10.8% projected to $330.69 billion by 2030, driven by innovative policies and emerging biotechnologies[67]. - In the first half of 2023, national health expenditure reached ¥1,204 billion, a year-on-year increase of 6.9%, indicating sustained investment in healthcare infrastructure[70]. - The demand for smart laboratories in the life sciences sector is growing, with current penetration rates below 20%, indicating significant market potential[73]. - The government has set ambitious revenue targets for the biopharmaceutical industry, with annual R&D investment growth expected to exceed 10%[68]. - Continuous investment in medical infrastructure is emphasized, with a budget of ¥22.697 billion for health services in 2023, reflecting a 2.9% increase from the previous year[70]. - The industry is experiencing a shift towards domestic production, supported by local policies aimed at reducing reliance on imported products[74]. - The total investment in new medical infrastructure during the "14th Five-Year Plan" period is estimated at CNY 1,002.6 billion, focusing on high-quality public hospital development and grassroots healthcare[89].

经审阅《青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存放与使 用情况专项报告》，我们认为：该报告真实反映了公司 2023 年半年度募集资金管 理与使用的相关情况。2023 年 1 月 1 日至 2023 年 6 月 30 日期间，公司对募集 资金进行了专户存储和专项使用，并及时履行了相关信息披露义务，不存在违反 法律法规改变募集资金用途和损害公司股东利益的情形。我们同意公司 2023 年 半年度募集资金存放与使用情况专项报告。 青岛海尔生物医疗股份有限公司 独立董事关于公司 2023 年半年度募集资金存放与使 用情况的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则》以及《青岛海尔生物医疗股份有限公司章程》《青岛海尔 生物医疗股份有限公司独立董事制度》等有关法律、法规、规章、规范性文件的 规定，我们作为青岛海尔生物医疗股份有限公司（以下简称"公司"）的独立董 事，对公司编制的《青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存 放与使用情况专项报告》进行了认真审阅，现基于独立判断的立场，发表如下独 立意见： 独立董事：陈洁、罗进、邹殿新、黄 ...

青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第二届监事会第十四次会议于 2023 年 8 月 29 日以现场结合通讯方式召 开，现场会议在青岛市高新区丰源路 280 号海尔生物医疗新兴产业园办公楼 101 举行。本次会议的通知于 2023 年 8 月 18 日以电子邮件方式送达全体监事。本次 会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席江兰主持。会议的 召集和召开程序符合有关法律法规、规范性文件和公司章程的规定，会议决议合 法、有效。 二、监事会会议审议情况 本次会议由监事会主席江兰主持，经全体监事认真审议并表决，本次会议通 过了如下议案： 证券代码：688139 证券简称：海尔生物 公告编号：2023-029 青岛海尔生物医疗股份有限公司 第二届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 经审议，公司监事会认为：公司报告期内对募集资金的存放与使用符合《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 ...

证券代码：688139 证券简称：海尔生物 公告编号：2023-030 青岛海尔生物医疗股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经上海证券交易所科创板股票上市委员会于 2019 年 7 月 30 日审核同意，并 经中国证券监督管理委员会于 2019 年 9 月 20 日下发《关于同意青岛海尔生物医 疗股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核 准，青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（普通合伙）审验并出具了《验资 ...

集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 青岛海尔生物医疗股份有限公司 关于参加 2023 年半年度医疗器械及医疗设备行业 证券代码：688139 证券简称：海尔生物 公告编号：2023-028 投资者可于 2023 年 8 月 30 日（星期三）至 2023 年 9 月 4 日(星期一)16:00 前通过邮件（haierbiomedical@haierbiomedical.com）、电话（0532-88935566） 等方式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者 普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于 2023 年 8 月 30 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 年半年度 医疗器械及医疗设备行业集体业绩说明会，此次活动将采用网络文字互动的方式举 行，投资者可登录上海证券交易所上证路演中心（http: ...

Financial Performance - Domestic market revenue grew by 17.77% year-on-year in Q1 2023, while overseas market revenue increased by 31.19%[5] - The company achieved operating revenue of CNY 686,668,622.18, representing a year-on-year increase of 21.87%[50] - Net profit attributable to shareholders reached CNY 137,535,031.82, up 21.15% compared to the same period last year[50] - Net profit for Q1 2023 was ¥139,509,813.51, representing a 22.5% increase from ¥113,932,456.54 in Q1 2022[73] - Basic and diluted earnings per share were both ¥0.43, reflecting a year-on-year increase of 19.44%[11] - Basic and diluted earnings per share were both CNY 0.43, compared to CNY 0.36 in the same period last year[62] Cash Flow and Assets - Net cash flow from operating activities reached approximately ¥106.25 million, representing an increase of 8.78%[11] - Cash flow from operating activities generated a net amount of ¥106.25 million, up from ¥97.67 million in the previous period[40] - Cash flow from operating activities in Q1 2023 was ¥622,326,845.23, an increase from ¥570,087,834.27 in Q1 2022[74] - Cash and cash equivalents at the end of the period amounted to approximately ¥1.26 billion, down from ¥1.67 billion at the end of the previous year[24] - The company reported a net increase in cash and cash equivalents of approximately ¥329.44 million during the quarter[24] - Total assets at the end of the reporting period were approximately ¥5.53 billion, up 0.69% from the end of the previous year[11] - As of March 31, 2023, total assets amounted to ¥5.53 billion, showing a slight increase from ¥5.49 billion[36] - The company's total current assets decreased to ¥3,224,795,967.12 in Q1 2023 from ¥3,488,519,972.93 in Q1 2022, a decline of 7.6%[70] - Non-current assets increased to ¥2,301,977,619.64 in Q1 2023 from ¥2,000,475,868.79 in Q1 2022, reflecting a growth of 15.1%[70] Liabilities and Equity - The total liabilities decreased from ¥1.34 billion to ¥1.24 billion, indicating improved financial health[36] - The company’s equity attributable to shareholders increased by 3.40% year-on-year, reaching approximately ¥4.16 billion[11] - Total equity attributable to shareholders of the parent company was CNY 4,157,390,941.28, an increase from CNY 4,020,637,920.82[60] Research and Development - R&D investment totaled approximately ¥80.01 million, accounting for 11.65% of operating revenue, a decrease of 0.42 percentage points[11] - Research and development expenses for Q1 2023 amounted to ¥80,011,141.60, compared to ¥68,022,389.62 in Q1 2022, indicating a 17.5% increase[73] Operational Highlights - The company accelerated the layout of new product solutions, focusing on automation sample libraries, biocultures, and laboratory consumables, which are becoming new growth drivers[28] - In Q1 2023, the company's gross margin increased to 51.02%, reflecting improved operational capabilities[29] - The life sciences segment grew by 19.02%, while the medical innovation segment increased by 24.89%[51] - The Internet of Things solutions business experienced a year-on-year growth of 23.34%[51] - The company completed the acquisition of Thick Hong Intelligent Technology, enhancing its automation solution matrix for hospital users[28] - The company launched new AI automation vaccine workstations and digital public health examination solutions, expanding its offerings in public health[28] Awards and Recognition - The company was awarded the "China Industrial Grand Prize," the highest award in the industrial sector, and recognized as a national green factory[28] Other Financial Metrics - The company’s financial expenses increased by ¥400.30 million, primarily due to changes in exchange gains and losses during the reporting period[8] - The company received a VAT refund of approximately ¥5.82 million, classified as a regular profit and loss item, benefiting from national policy[30] - Cash flow from investment activities yielded a net amount of ¥243.63 million, a decrease from ¥879.11 million year-on-year[40] - Other comprehensive income after tax for Q1 2023 was ¥98,055.44, compared to a loss of ¥129,606.57 in Q1 2022[73] - Total operating costs for Q1 2023 were ¥557,268,271.77, up from ¥461,609,356.07 in Q1 2022, reflecting a 20.7% increase[72]

证券代码：688139 证券简称：海尔生物 公告编号：2023-020 青岛海尔生物医疗股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 27 日(星期四)16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在文字互动环节对投 资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司参与了由上海证券交易所主办的 2022 年度医疗器 械专场集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投 资者可登录上海证券交 ...

Financial Performance - In 2022, the company's operating income reached ¥2,864,044,617.29, representing a year-on-year increase of 34.72%[32]. - The net profit attributable to shareholders was ¥600,791,263.18, a decrease of 28.90% compared to the previous year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥532,875,645.95, an increase of 27.47% year-on-year[32]. - The company's total assets at the end of 2022 amounted to ¥5,488,995,841.72, reflecting a 12.02% increase from the previous year[32]. - The basic earnings per share for 2022 was ¥1.89, down 29.21% from ¥2.67 in 2021[32]. - The company's net assets attributable to shareholders increased by 10.98% to ¥4,020,637,920.82 by the end of 2022[32]. - The company reported a net cash flow from operating activities of ¥632,429,327.27, an increase of 6.87% year-on-year[32]. Dividend and Share Capital - The company plans to distribute a cash dividend of 4.5 RMB per 10 shares, totaling approximately 142.42 million RMB (including tax) based on a total share capital of 317,952,508 shares as of December 31, 2022[7]. - The company has a total share capital of 317,952,508 shares, with 1,459,586 shares held in a repurchase account, affecting the dividend distribution calculation[7]. - The company has a total share count of 317,952,508 after the issuance of 880,750 new shares, with 58.15% being unrestricted circulating shares[149]. - The company plans to repurchase up to 1 million shares, which would account for approximately 0.32% of the total share capital, with a maximum repurchase price of 100 RMB per share[194]. - The lower limit of the repurchase plan estimates around 500,000 shares, representing about 0.16% of the total share capital[194]. Corporate Governance - The audit report issued by Ernst & Young Huaming confirms the financial statements' accuracy and completeness, providing assurance to stakeholders[6]. - The company has confirmed that all board members attended the board meeting, ensuring governance and oversight in decision-making processes[10]. - The company has not disclosed any special arrangements in corporate governance, indicating standard practices are in place[15]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[15]. - The company has not violated decision-making procedures for external guarantees, indicating adherence to regulatory compliance[15]. - The company has not disclosed any related party transactions among the top ten shareholders, ensuring transparency in ownership[188]. - The company is committed to maintaining its corporate governance standards, as evidenced by the absence of undisclosed related party relationships among shareholders[188]. Strategic Development and Future Plans - The company has outlined its future plans and strategic development in the annual report, although these do not constitute binding commitments to investors[12]. - The company is actively expanding its market presence, particularly in the life sciences and healthcare sectors, driven by national strategies promoting technological innovation and healthcare services[74]. - The company has established a "dual carbon" task force to promote green and low-carbon development across various departments[38]. - The company has a commitment to not transfer or reduce its shareholdings for a period of three months starting from October 25, 2022[58]. - The company has committed to limiting the annual transfer of shares to no more than 25% of the total shares held during its tenure as a director or senior management[58]. Research and Development - The company invested 10.21% of its operating income in R&D, a decrease of 0.91 percentage points from the previous year[32]. - The company introduced over 30 new products in microbiological culture media and protein expression technology, expanding its market in biopharmaceutical research and industrial production[90]. - The company increased its patent portfolio by 50%, with a total of 271 new patents filed in 2022, including 11 invention patents[90]. - The company has made significant advancements in automation technology, including a self-innovated -80℃ automated biological sample storage technology[87]. - The company is focused on enhancing its technological capabilities to meet the growing demand for comprehensive solutions in biological experiments, drug development, and medical services[74]. Market Expansion - The company's overseas market revenue reached 83,389.89 million yuan, representing a year-on-year growth of 56.45%[82]. - The domestic market generated revenue of CNY 2,021.53 million, reflecting a year-on-year growth of 27.50%[175]. - The company expanded its overseas distribution network to over 700, covering 8 new countries in Central and Eastern Europe[176]. - The company has established long-term partnerships with over 40 international organizations, including WHO and UNICEF[153]. - The company has successfully broken foreign monopolies in biomedical low-temperature technology and has received the only National Science and Technology Progress Award in the industry[152]. Operational Efficiency - The company has optimized its entire value chain through digitalization, enhancing operational efficiency across various departments[151]. - The company maintains a complete control process from customer demand collection to after-sales service, ensuring operational consistency[158]. - The company has implemented a production management system to ensure product quality meets regulatory requirements, including monitoring and measurement controls[67]. - The company has a structured approach to supplier qualification and procurement, ensuring that suppliers are vetted before entering the supplier database[65]. Financial Management - The total amount of funds raised through public stock issuance was approximately ¥1.23 billion, with a net amount of ¥1.16 billion after deducting issuance costs[113]. - The cumulative investment amount in fundraising projects reached approximately ¥605.94 million, representing a progress rate of 60.59%[113]. - The company plans to use up to ¥650 million of temporarily idle fundraising for cash management, investing in safe and liquid products[118]. - The company has invested approximately ¥10.82 billion in principal-protected financial products, with an outstanding balance of ¥1.49 billion[125]. - The company has issued structured deposits totaling ¥6 billion, with interest rates ranging from 1.3% to 3.29%[108].

1 证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |----------------|-------------------------------------|---------|---------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ | 分析师会议 | | 类别 | □媒体采访 | □ | 业绩说明会 | | | □新闻发布会 | □ | 路演活动 | | | □现场参观 | □ | 电话会议 | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 共 267 | | 家机构，参会机构名单详见附表。 | | 时间 | 2022 年 4 月 29 日— 5 | 月 13 | 日 | | 参会方式 | 电话会议 | | | | 上市公司接待 ...

1 证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | --- | |-----------------------|---------------------------------------|---------|-----------------------------------------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ | 分析师会议 | | 类别 | □媒体采访 | □ | 业绩说明会 | | | □新闻发布会 | □ | 路演活动 | | | □现场参观 | □ | 电话会议 | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 共 157 构，参会机构名单详见附表。 | | | | 时间 | 2022 年 5 月 17 日— 6 | 月 17 | 日 | | 参会方式 | 电话会议、现场会议 | | | | 上市公司接待人 员姓名 | 董事会秘书黄艳莉、证券事务代表蒋宏建 | | | | ...